FANDOM SPORTS Media Corp. (CSE: FDM) (OTCQB: FDMSF) (FRA:

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
319
FANDOM SPORTS Media Corp. (CSE: FDM) (OTCQB: FDMSF) (FRA: TQ42) App Set to Reach Market of 130 Million across 161 Countries

- Widespread global use of smartphones make them an ideal marketing platform
- Samsung is number one in smartphone market
- FANDOM SPORTS App approved for Samsung Galaxy App Store

The digital age has made the smartphone almost as ubiquitous as water on the planet. Go where you might; it’s unlikely you’ll be very far from mobile service. Even those attempting to scale Mt.
Everest will be able to use their mobile phones, as far up as base camp, set at 18,000 feet, more than halfway up the mountain’s 29,029-foot peak. Such widespread adoption makes the smartphone the ideal vehicle to market and distribute a product, like the one being offered by FANDOM SPORTS Media Corp. (CSE: FDM) (OTCQB: FDMSF) (FRANKFURT: TQ42). The company has announced that its Android version mobile sports app has gained Galaxy App Store approval. Acceptance into the Samsung Galaxy App Store will ensure high quality exposure to Android users of Galaxy versions 7, 8 & 9, as well as future versions of Samsung’s Galaxy devices (http://nnw.fm/J8Za7).

Despite its attractive associations and loyal fan base, on a global basis, the Apple brand is not first choice for many smartphone owners. That prized position is held by Samsung, which, according to Statista, shipped 317.3 million smartphones in 2017 (http://nnw.fm/2NI6p). The South Korean company has consistently outsold rivals with its Galaxy line, first introduced in April 2009. It continues in the top spot with a market share around 20 percent. Applications specially designed for its phones are available from its “Galaxy Apps” online store, which Samsung has said will ‘eventually reach more than 130 million users across 161 countries’, according to PC Magazine (http://nnw.fm/JSfm0). On such a global platform, the FANDOM SPORTS App will undoubtedly find application to a wide variety of sports.

The app was developed to provide sports fans around the world an uncensored social media platform that will allow them to express enthusiasm for their chosen games. It brings together fans in a social media setting, which many now find more comfortable and more convenient than traditional forums of physical interaction. The app is designed to entertain sports enthusiasts with real-time, interactive content that offers bragging rights and real-life rewards. True sports addicts will appreciate the app, which allows fans to pick a fight, create their own FanFights or rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric “argument engine” measures and scores opinionated dialogue and establishes consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

To touch base with sports fans, FANDOM SPORTS Media has hired an industry leading mobile app marketing and strategy firm to conduct aggressive marketing outreach (http://nnw.fm/KSr0v). The campaign is designed to increase growth and discovery, drive engagement, refine potential revenue opportunities and better position the FANDOM SPORTS App for the successful rollout of its v2 product, which is scheduled for release in early Q4 2018. The v2 product is expected to have a simultaneous Android and iOS release date, with the trash-talking theme being parlayed around a “gamified” approach, utilizing elements of the micro-betting of FANCOINS.

The company is employing the tagline, “Pick a Fight”, signaling that it intends to go about acquiring users through an appeal to their competitive instincts… an appropriate strategy in the land of free competition.

For more information, visit the company’s website at www.FANDOMSPORTS.net

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Fandom Sports Media Corp. (FDMSF) Stock Research Links

FDMSF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading

Top 5 Most Recently Viewed Articles

A Comprehensive Look at Apple's Competitive Position in Tech

Updated Category News Views 313

Understanding Apple's Competitive Landscape In today's dynamic business environment, a deep-dive analysis of top companies is essential for investors and industry insiders. This examination will focus on Apple (AAPL), alongside its chief rivals in the Technology Hardware, Storage & Peripherals sector. By analyzing crucial financial indicators, market positioning, and...

Continue Reading
Cegedim Shares Insights on Latest Liquidity Contract Performance

Updated Category News Views 135

Overview of Cegedim's Liquidity Contract Statement This article covers the latest updates on Cegedim’s liquidity contract performance, highlighting significant figures and trends that reflect the company's financial health. Cegedim has established a robust liquidity contract with Rothschild Martin Maurel, aimed at promoting transparency and liquidity in its shares. Key...

Continue Reading
Silexion Therapeutics Advances SIL204 for Pancreatic Cancer

Updated Category News Views 136

Silexion Therapeutics Moves Forward with SIL204 Silexion Therapeutics Corp. (NASDAQ: SLXN) is celebrating a significant milestone with the completion of crucial toxicology studies for its innovative RNA silencing therapy, SIL204. This groundbreaking therapy, designed to target mutated KRAS oncogenes, has shown no signs of systemic organ toxicity, reinforcing the...

Continue Reading
Emerson Partners with LifeSight for Enhanced Pension Solutions

Updated Category News Views 178

Emerson Partners with LifeSight for Pension Solutions LifeSight, WTW’s UK defined contribution (DC) master trust, has stepped into a significant role by becoming the full master trust provider for Emerson, the advanced electronics powerhouse. This partnership aims to cover all active, deferred, and drawdown members effectively, ensuring they are well-accommodated in...

Continue Reading
Howard Marks Joins Alliance for Decision Education Board

Updated Category News Views 227

Exciting News from the Alliance for Decision Education The Alliance for Decision Education is thrilled to announce an important addition to its Board of Directors. Howard Marks, a leader in investment management and a well-respected voice in decision-making, has agreed to join the board. As the co-chairman and co-founder of Oaktree Capital Management, Marks brings with...

Continue Reading